Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Autoimmune Disorders

  Free Subscription


Articles published in Brain

Retrieve available abstracts of 132 articles:
HTML format



Single Articles


    April 2021
  1. PISA M, Croese T, Dalla Costa G, Guerrieri S, et al
    Subclinical anterior optic pathway involvement in early multiple sclerosis and clinically isolated syndromes.
    Brain. 2021 Apr 8. pii: 6215108. doi: 10.1093.
    PubMed     Abstract available


  2. LUCCHESE G, Floel A
    Guillain-Barre syndrome, SARS-CoV-2 and molecular mimicry.
    Brain. 2021 Apr 3. pii: 6209729. doi: 10.1093.
    PubMed    


  3. LUNN MP, Carr AC, Keddie S, Pakpoor J, et al
    Reply: Guillain-Barre syndrome, SARS-CoV-2 and molecular mimicry and Ongoing challenges in unravelling the association between COVID-19 and Guillain-Barre syndrome and Unclear association between COVID-19 and Guillain-Barre syndrome and Currently avai
    Brain. 2021 Apr 3. pii: 6209732. doi: 10.1093.
    PubMed    


  4. FOSCHI M, D'Anna L, Abdelhak A, Mayer B, et al
    Ongoing challenges in unravelling the association between COVID-19 and Guillain-Barre syndrome.
    Brain. 2021 Apr 3. pii: 6209733. doi: 10.1093.
    PubMed    


  5. GONZALEZ DEL CASTILLO J, Porta-Etessam J, Miro O
    Currently available data regarding the potential association between COVID-19 and Guillain-Barre syndrome.
    Brain. 2021 Apr 3. pii: 6209731. doi: 10.1093.
    PubMed    


    March 2021
  6. ONTANEDA D, Raza PC, Mahajan KR, Arnold DL, et al
    Deep grey matter injury in multiple sclerosis: A NAIMS consensus statement.
    Brain. 2021 Mar 23. pii: 6184142. doi: 10.1093.
    PubMed     Abstract available


  7. VOGRIG A, Moritz CP, Camdessanche JP, Tholance Y, et al
    Unclear association between COVID-19 and Guillain-Barre syndrome.
    Brain. 2021 Mar 23. pii: 6181752. doi: 10.1093.
    PubMed    


  8. BHARGAVA P, Kim S, Reyes AA, Grenningloh R, et al
    Imaging meningeal inflammation in CNS autoimmunity identifies a therapeutic role for BTK inhibition.
    Brain. 2021 Mar 16. pii: 6173632. doi: 10.1093.
    PubMed     Abstract available


  9. SABEL CE, Pearson JF, Mason DF, Willoughby E, et al
    The latitude gradient for multiple sclerosis prevalence is established in the early lifecourse.
    Brain. 2021 Mar 11. pii: 6168130. doi: 10.1093.
    PubMed     Abstract available


  10. RAHMANZADEH R, Lu PJ, Barakovic M, Weigel M, et al
    Myelin and axon pathology in multiple sclerosis assessed by myelin water and multi-shell diffusion imaging.
    Brain. 2021 Mar 9. pii: 6164965. doi: 10.1093.
    PubMed     Abstract available


  11. MITSDORFFER M, Di Liberto G, Dotsch S, Sie C, et al
    Formation and immunomodulatory function of meningeal B-cell aggregates in progressive CNS autoimmunity.
    Brain. 2021 Mar 9. pii: 6164962. doi: 10.1093.
    PubMed     Abstract available


  12. XU Y, Smith KA, Hiyoshi A, Piehl F, et al
    Hospital-diagnosed infections before age 20 and risk of a subsequent multiple sclerosis diagnosis.
    Brain. 2021 Mar 9. pii: 6164964. doi: 10.1093.
    PubMed     Abstract available


    February 2021
  13. KILPATRICK TJ, Binder MD
    Neuregulin therapy for multiple sclerosis: an each-way bet?
    Brain. 2021;144:6-8.
    PubMed    


    January 2021
  14. DAL-BIANCO A, Grabner G, Kronnerwetter C, Weber M, et al
    Long-term evolution of multiple sclerosis iron rim lesions in 7 T MRI.
    Brain. 2021 Jan 23. pii: 6114694. doi: 10.1093.
    PubMed     Abstract available



  15. Corrigendum to: Quantitative spinal cord MRI in MOG-antibody disease, neuromyelitis optica and multiple sclerosis.
    Brain. 2021 Jan 11. pii: 6082765. doi: 10.1093.
    PubMed    


    December 2020
  16. KIM K, Probstel AK, Baumann R, Dyckow J, et al
    Cell type-specific transcriptomics identifies neddylation as a novel therapeutic target in multiple sclerosis.
    Brain. 2020 Dec 29. pii: 6055080. doi: 10.1093.
    PubMed     Abstract available


  17. HALDER SK, Milner R
    Hypoxia in multiple sclerosis; is it the chicken or the egg?
    Brain. 2020 Dec 22. pii: 6044083. doi: 10.1093.
    PubMed     Abstract available


  18. LUNN MP, Cornblath DR, Jacobs BC, Querol L, et al
    COVID-19 vaccine and Guillain-Barre syndrome: let's not leap to associations.
    Brain. 2020 Dec 14. pii: 6031904. doi: 10.1093.
    PubMed    


  19. KEDDIE S, Pakpoor J, Mousele C, Pipis M, et al
    Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barre syndrome.
    Brain. 2020 Dec 14. pii: 6031905. doi: 10.1093.
    PubMed     Abstract available


  20. KATARIA H, Hart CG, Alizadeh A, Cossoy M, et al
    Neuregulin-1 beta 1 is implicated in pathogenesis of multiple sclerosis.
    Brain. 2020 Dec 13. pii: 6032483. doi: 10.1093.
    PubMed     Abstract available


  21. HOHLFELD R, Beltran E, Gerdes LA, Dornmair K, et al
    Tissue-resident CD8+ memory T cells in multiple sclerosis.
    Brain. 2020 Dec 13. pii: 6032479. doi: 10.1093.
    PubMed    


  22. SMOLDERS J, Fransen NL, Huitinga I, Hamann J, et al
    Reply: Tissue-resident CD8+ memory T cells in multiple sclerosis.
    Brain. 2020 Dec 13. pii: 6032480. doi: 10.1093.
    PubMed    


  23. EFTIMOV F, Lucke IM, Querol LA, Rajabally YA, et al
    Diagnostic challenges in chronic inflammatory demyelinating polyradiculoneuropathy.
    Brain. 2020;143:3214-3224.
    PubMed     Abstract available


  24. PATERSON RW, Brown RL, Vivekanandam V, Foulkes AJM, et al
    Reply: Concentric demyelination pattern in COVID-19-associated acute haemorrhagic leukoencephalitis: a lurking catastrophe?
    Brain. 2020;143:e101.
    PubMed    


  25. KARAPANAYIOTIDES T, Geka E, Prassopoulos P, Koutroulou I, et al
    Concentric demyelination pattern in COVID-19-associated acute haemorrhagic leukoencephalitis: a lurking catastrophe?
    Brain. 2020;143:e100.
    PubMed    


  26. CAO A, Rohaut B, Le Guennec L, Saheb S, et al
    Severe COVID-19-related encephalitis can respond to immunotherapy.
    Brain. 2020;143:e102.
    PubMed    


    November 2020
  27. PETROU P, Kassis I, Levin N, Paul F, et al
    Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis.
    Brain. 2020 Nov 30. pii: 6012789. doi: 10.1093.
    PubMed     Abstract available


  28. PETZOLD A, Chua SYL, Khawaja AP, Keane PA, et al
    Retinal asymmetry in multiple sclerosis.
    Brain. 2020 Nov 30. pii: 6012795. doi: 10.1093.
    PubMed     Abstract available


  29. SCHIAVI S, Petracca M, Sun P, Fleysher L, et al
    Non-invasive quantification of inflammation, axonal and myelin injury in multiple sclerosis.
    Brain. 2020 Nov 30. pii: 5999115. doi: 10.1093.
    PubMed     Abstract available


  30. STERIADE C, Titulaer MJ, Vezzani A, Sander JW, et al
    The association between systemic autoimmune disorders and epilepsy and its clinical implications.
    Brain. 2020 Nov 22. pii: 5998333. doi: 10.1093.
    PubMed     Abstract available


  31. DE MEO E, Storelli L, Moiola L, Ghezzi A, et al
    In vivo gradients of thalamic damage in paediatric multiple sclerosis: a window into pathology.
    Brain. 2020 Nov 21. pii: 5998271. doi: 10.1093.
    PubMed     Abstract available


  32. MARIANO R, Messina S, Roca-Fernandez A, Leite MI, et al
    Quantitative spinal cord MRI in MOG-antibody disease, neuromyelitis optica and multiple sclerosis.
    Brain. 2020 Nov 18. pii: 5989776. doi: 10.1093.
    PubMed     Abstract available


  33. ELLENBERGER D, Flachenecker P, Fneish F, Frahm N, et al
    Aggressive multiple sclerosis - a matter of measurement and timing.
    Brain. 2020 Nov 11. pii: 5974108. doi: 10.1093.
    PubMed    


  34. KALINCIK T, Malpas CB
    Reply: Aggressive multiple sclerosis - a matter of measurement and timing.
    Brain. 2020 Nov 11. pii: 5974107. doi: 10.1093.
    PubMed    


    October 2020
  35. SUCKSDORFF M, Matilainen M, Tuisku J, Polvinen E, et al
    Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis.
    Brain. 2020 Oct 2. pii: 5917253. doi: 10.1093.
    PubMed     Abstract available


  36. GAUDIOSO C, Naismith RT
    Optimizing treatment strategies in paediatric, adult and late-onset multiple sclerosis.
    Brain. 2020;143:2866-2868.
    PubMed    


    September 2020
  37. AMATO MP, Fonderico M, Portaccio E, Pasto L, et al
    Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis.
    Brain. 2020 Sep 16. pii: 5906150. doi: 10.1093.
    PubMed     Abstract available


  38. OUELLETTE R, Treaba CA, Granberg T, Herranz E, et al
    7 T imaging reveals a gradient in spinal cord lesion distribution in multiple sclerosis.
    Brain. 2020 Sep 16. pii: 5906152. doi: 10.1093.
    PubMed     Abstract available


  39. WAGNON I, Helie P, Bardou I, Regnauld C, et al
    Autoimmune encephalitis mediated by B-cell response against N-methyl-d-aspartate receptor.
    Brain. 2020 Sep 7. pii: 5902131. doi: 10.1093.
    PubMed     Abstract available


  40. GERALDES R, Esiri MM, Perera R, Yee SA, et al
    Vascular disease and multiple sclerosis: a post-mortem study exploring their relationships.
    Brain. 2020 Sep 2. pii: 5900415. doi: 10.1093.
    PubMed     Abstract available


  41. ROOS I, Leray E, Frascoli F, Casey R, et al
    Delay from treatment start to full effect of immunotherapies for multiple sclerosis.
    Brain. 2020;143:2742-2756.
    PubMed     Abstract available


  42. KULLMANN DM
    Editorial.
    Brain. 2020;143:2625.
    PubMed    


  43. RICHARD C, Ruiz A, Cavagna S, Bigotte M, et al
    Connexins in neuromyelitis optica: a link between astrocytopathy and demyelination.
    Brain. 2020;143:2721-2732.
    PubMed     Abstract available


  44. MANNARA F, Radosevic M, Planaguma J, Soto D, et al
    Allosteric modulation of NMDA receptors prevents the antibody effects of patients with anti-NMDAR encephalitis.
    Brain. 2020;143:2709-2720.
    PubMed     Abstract available


    August 2020
  45. BOUMAN PM, Steenwijk MD, Pouwels PJW, Schoonheim MM, et al
    Histopathology-validated recommendations for cortical lesion imaging in multiple sclerosis.
    Brain. 2020 Aug 21. pii: 5895168. doi: 10.1093.
    PubMed     Abstract available


  46. CHITNIS T, Aaen G, Belman A, Benson L, et al
    Improved relapse recovery in paediatric compared to adult multiple sclerosis.
    Brain. 2020 Aug 18. pii: 5894047. doi: 10.1093.
    PubMed     Abstract available


    July 2020
  47. SORENSEN PS, Sellebjerg F, Hartung HP, Montalban X, et al
    The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history.
    Brain. 2020 Jul 24. pii: 5876125. doi: 10.1093.
    PubMed     Abstract available


    June 2020
  48. JACKLE K, Zeis T, Schaeren-Wiemers N, Junker A, et al
    Molecular signature of slowly expanding lesions in progressive multiple sclerosis.
    Brain. 2020 Jun 24. pii: 5861738. doi: 10.1093.
    PubMed     Abstract available


  49. KERBRAT A, Gros C, Badji A, Bannier E, et al
    Multiple sclerosis lesions in motor tracts from brain to cervical cord: spatial distribution and correlation with disability.
    Brain. 2020 Jun 23. pii: 5861019. doi: 10.1093.
    PubMed     Abstract available


  50. ZEKERIDOU A, Pittock SJ
    Synaptic autoimmunity: new insights into LGI1 antibody-mediated neuronal dysfunction.
    Brain. 2020;143:1622-1625.
    PubMed    


    May 2020
  51. RAMBERGER M, Berretta A, Tan JMM, Sun B, et al
    Distinctive binding properties of human monoclonal LGI1 autoantibodies determine pathogenic mechanisms.
    Brain. 2020 May 21. pii: 5841730. doi: 10.1093.
    PubMed     Abstract available


  52. FRANSEN NL, Hsiao CC, van der Poel M, Engelenburg HJ, et al
    Tissue-resident memory T cells invade the brain parenchyma in multiple sclerosis white matter lesions.
    Brain. 2020 May 13. pii: 5836675. doi: 10.1093.
    PubMed     Abstract available


  53. MALPAS CB, Manouchehrinia A, Sharmin S, Roos I, et al
    Early clinical markers of aggressive multiple sclerosis.
    Brain. 2020 May 9. pii: 5835340. doi: 10.1093.
    PubMed     Abstract available


  54. KADOWAKI A, Quintana FJ
    The NLRP3 inflammasome in progressive multiple sclerosis.
    Brain. 2020;143:1286-1288.
    PubMed    


  55. TAKAI Y, Misu T, Kaneko K, Chihara N, et al
    Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study.
    Brain. 2020;143:1431-1446.
    PubMed     Abstract available


    April 2020
  56. DIETRICH M, Koska V, Hecker C, Gottle P, et al
    Protective effects of 4-aminopyridine in experimental optic neuritis and multiple sclerosis.
    Brain. 2020 Apr 15. pii: 5820386. doi: 10.1093.
    PubMed     Abstract available


  57. MALHOTRA S, Costa C, Eixarch H, Keller CW, et al
    NLRP3 inflammasome as prognostic factor and therapeutic target in primary progressive multiple sclerosis patients.
    Brain. 2020 Apr 13. pii: 5819591. doi: 10.1093.
    PubMed     Abstract available


    March 2020
  58. KLEEREKOOPER I, Petzold A, Trip SA
    Anterior visual system imaging to investigate energy failure in multiple sclerosis.
    Brain. 2020 Mar 12. pii: 5804129. doi: 10.1093.
    PubMed     Abstract available


    January 2020
  59. ROWE J
    Editorial.
    Brain. 2020;143:1.
    PubMed    


    November 2019
  60. MEIJER KA, Steenwijk MD, Douw L, Schoonheim MM, et al
    Long-range connections are more severely damaged and relevant for cognition in multiple sclerosis.
    Brain. 2019 Nov 15. pii: 5626204. doi: 10.1093.
    PubMed     Abstract available


    October 2019
  61. HAUSLER D, Torke S, Peelen E, Bertsch T, et al
    Reply: Hypercalcaemia rather than high dose vitamin D3 supplements could exacerbate multiple sclerosis.
    Brain. 2019 Oct 30. pii: 5610115. doi: 10.1093.
    PubMed    


  62. SMOLDERS J, Damoiseaux J, Hupperts R
    Hypercalcaemia rather than high dose vitamin D3 supplements could exacerbate multiple sclerosis.
    Brain. 2019 Oct 30. pii: 5610116. doi: 10.1093.
    PubMed    


  63. SABBAGH S, Almeida de Jesus A, Hwang S, Kuehn HS, et al
    Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib.
    Brain. 2019 Oct 11. pii: 5585662. doi: 10.1093.
    PubMed    


  64. LANDON-CARDINAL O, Benveniste O, Allenbach Y
    Reply: Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib.
    Brain. 2019 Oct 11. pii: 5585663. doi: 10.1093.
    PubMed    


  65. CRISP SJ, Dixon CL, Jacobson L, Chabrol E, et al
    Glycine receptor autoantibodies disrupt inhibitory neurotransmission.
    Brain. 2019 Oct 8. pii: 5583666. doi: 10.1093.
    PubMed     Abstract available


  66. NUTMA E, Stephenson JA, Gorter RP, de Bruin J, et al
    A quantitative neuropathological assessment of translocator protein expression in multiple sclerosis.
    Brain. 2019 Oct 3. pii: 5580333. doi: 10.1093.
    PubMed     Abstract available


  67. KARAKAYA M, Wirth B
    Hereditary nodo-paranodopathies: genomic variants, not just autoantibodies, hit the protein.
    Brain. 2019;142:2895-2897.
    PubMed    


    September 2019
  68. ELLIOTT C, Belachew S, Wolinsky JS, Hauser SL, et al
    Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis.
    Brain. 2019;142:2787-2799.
    PubMed     Abstract available


  69. PENNER IK, Hartung HP
    The dark side of the moon: looking beyond beneficial effects of cannabis use in multiple sclerosis.
    Brain. 2019;142:2552-2555.
    PubMed    


  70. BENVENISTE O, Allenbach Y
    Inclusion body myositis: accumulation of evidence for its autoimmune origin.
    Brain. 2019;142:2549-2551.
    PubMed    


    August 2019
  71. MORQUETTE B, Juzwik CA, Drake SS, Charabati M, et al
    MicroRNA-223 protects neurons from degeneration in experimental autoimmune encephalomyelitis.
    Brain. 2019 Aug 14. pii: 5549993. doi: 10.1093.
    PubMed     Abstract available


  72. BROWNLEE WJ, Altmann DR, Prados F, Miszkiel KA, et al
    Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis.
    Brain. 2019;142:2276-2287.
    PubMed     Abstract available


    July 2019
  73. FEINSTEIN A, Meza C, Stefan C, Staines RW, et al
    Coming off cannabis: a cognitive and magnetic resonance imaging study in patients with multiple sclerosis.
    Brain. 2019 Jul 30. pii: 5541023. doi: 10.1093.
    PubMed     Abstract available


  74. WENTLING M, Lopez-Gomez C, Park HJ, Amatruda M, et al
    A metabolic perspective on CSF-mediated neurodegeneration in multiple sclerosis.
    Brain. 2019 Jul 15. pii: 5531715. doi: 10.1093.
    PubMed     Abstract available


  75. HAUSLER D, Torke S, Peelen E, Bertsch T, et al
    High dose vitamin D exacerbates central nervous system autoimmunity by raising T-cell excitatory calcium.
    Brain. 2019 Jul 13. pii: 5532100. doi: 10.1093.
    PubMed     Abstract available


  76. FITZGERALD KC, Kim K, Smith MD, Aston SA, et al
    Early complement genes are associated with visual system degeneration in multiple sclerosis.
    Brain. 2019 Jul 9. pii: 5530228. doi: 10.1093.
    PubMed     Abstract available


  77. ROPELE S, Fazekas F
    Quantification of cortical damage in multiple sclerosis using DTI remains a challenge.
    Brain. 2019;142:1848-1850.
    PubMed    


    June 2019
  78. FILIPPI M, Preziosa P, Banwell BL, Barkhof F, et al
    Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines.
    Brain. 2019 Jun 17. pii: 5519813. doi: 10.1093.
    PubMed     Abstract available


  79. PREZIOSA P, Kiljan S, Steenwijk MD, Meani A, et al
    Axonal degeneration as substrate of fractional anisotropy abnormalities in multiple sclerosis cortex.
    Brain. 2019 Jun 5. pii: 5511700. doi: 10.1093.
    PubMed     Abstract available


    May 2019
  80. MUNK NIELSEN N, Corn G, Frisch M, Stenager E, et al
    Multiple sclerosis among first- and second-generation immigrants in Denmark: a population-based cohort study.
    Brain. 2019 May 13. pii: 5488579. doi: 10.1093.
    PubMed     Abstract available


  81. COTZOMI E, Stathopoulos P, Lee CS, Ritchie AM, et al
    Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production.
    Brain. 2019 May 5. pii: 5485817. doi: 10.1093.
    PubMed     Abstract available


  82. GIOVANNONI G
    Survival: the ultimate long-term outcome in multiple sclerosis.
    Brain. 2019;142:1166-1167.
    PubMed    


  83. PALACE J, Lin DY, Zeng D, Majed M, et al
    Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders.
    Brain. 2019;142:1310-1323.
    PubMed     Abstract available


    April 2019
  84. VAN COEVORDEN-HAMEETE MH, de Bruijn MAAM, de Graaff E, Bastiaansen DAEM, et al
    The expanded clinical spectrum of anti-GABABR encephalitis and added value of KCTD16 autoantibodies.
    Brain. 2019 Apr 22. pii: 5476117. doi: 10.1093.
    PubMed     Abstract available


  85. WEKERLE H
    Secondary progressive multiple sclerosis and the gut-brain axis.
    Brain. 2019;142:838-840.
    PubMed    


    March 2019
  86. KINGWELL E, Leray E, Zhu F, Petkau J, et al
    Multiple sclerosis: effect of beta interferon treatment on survival.
    Brain. 2019 Mar 18. pii: 5382233. doi: 10.1093.
    PubMed     Abstract available


  87. HOHLFELD R
    Immune dysbalance in childhood multiple sclerosis: a 'chicken or the egg' conundrum.
    Brain. 2019;142:490-492.
    PubMed    


    February 2019
  88. KADOWAKI A, Saga R, Lin Y, Sato W, et al
    Gut microbiota-dependent CCR9+CD4+ T cells are altered in secondary progressive multiple sclerosis.
    Brain. 2019 Feb 15. pii: 5321131. doi: 10.1093.
    PubMed     Abstract available


  89. MEXHITAJ I, Nyirenda MH, Li R, O'Mahony J, et al
    Abnormal effector and regulatory T cell subsets in paediatric-onset multiple sclerosis.
    Brain. 2019 Feb 12. pii: 5316384. doi: 10.1093.
    PubMed     Abstract available


  90. ALLENBACH Y, Bolko L, Toquet S, Landon-Cardinal O, et al
    Reply: Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis.
    Brain. 2019 Feb 1. pii: 5305679. doi: 10.1093.
    PubMed    


  91. PAPADOPOULOU C, Hong Y, Omoyinmi E, Brogan PA, et al
    Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis.
    Brain. 2019 Feb 1. pii: 5305681. doi: 10.1093.
    PubMed    


    January 2019
  92. EDEN D, Gros C, Badji A, Dupont SM, et al
    Spatial distribution of multiple sclerosis lesions in the cervical spinal cord.
    Brain. 2019 Jan 30. pii: 5304670. doi: 10.1093.
    PubMed     Abstract available


  93. NTRANOS A, Ntranos V, Bonnefil V, Liu J, et al
    Fumarates target the metabolic-epigenetic interplay of brain-homing T cells in multiple sclerosis.
    Brain. 2019 Jan 28. pii: 5303708. doi: 10.1093.
    PubMed     Abstract available


  94. CHEN Y, Podojil JR, Kunjamma RB, Jones J, et al
    Sephin1, which prolongs the integrated stress response, is a promising therapeutic for multiple sclerosis.
    Brain. 2019 Jan 17. pii: 5289373. doi: 10.1093.
    PubMed     Abstract available


    December 2018
  95. VON ESSEN MR, Ammitzboll C, Hansen RH, Petersen ERS, et al
    Proinflammatory CD20+ T cells in the pathogenesis of multiple sclerosis.
    Brain. 2018 Dec 17. pii: 5250831. doi: 10.1093.
    PubMed     Abstract available


  96. KAUNZNER UW, Kang Y, Zhang S, Morris E, et al
    Quantitative susceptibility mapping identifies inflammation in a subset of chronic multiple sclerosis lesions.
    Brain. 2018 Dec 15. pii: 5250435. doi: 10.1093.
    PubMed     Abstract available


    November 2018
  97. ZALC B
    One hundred and fifty years ago Charcot reported multiple sclerosis as a new neurological disease.
    Brain. 2018 Nov 20. pii: 5194497. doi: 10.1093.
    PubMed    


  98. ALY L, Korn T
    Multiple sclerosis: is it all black and white in optical coherence tomography?
    Brain. 2018;141:3088-3091.
    PubMed    


  99. DEBANNE D, El Far O
    Pre- and postsynaptic effects of LGI1 autoantibodies in a murine model of limbic encephalitis.
    Brain. 2018;141:3092-3095.
    PubMed    


  100. AESCHLIMANN FA, Fremond ML, Duffy D, Rice GI, et al
    A child with severe juvenile dermatomyositis treated with ruxolitinib.
    Brain. 2018;141:e80.
    PubMed    


  101. ALLENBACH Y, Toquet S, Landon-Cardinal O, Benveniste O, et al
    Reply: A child with severe juvenile dermatomyositis treated with ruxolitinib.
    Brain. 2018;141:e81.
    PubMed    


    October 2018
  102. CALDITO NG, Saidha S, Sotirchos ES, Dewey BE, et al
    Brain and retinal atrophy in African-Americans versus Caucasian-Americans with multiple sclerosis: a longitudinal study.
    Brain. 2018 Oct 11. pii: 5127751. doi: 10.1093.
    PubMed     Abstract available


  103. DOETS AY, Verboon C, van den Berg B, Harbo T, et al
    Regional variation of Guillain-Barre syndrome.
    Brain. 2018;141:2866-2877.
    PubMed     Abstract available


    September 2018
  104. BAKER D, Pryce G, Amor S, Giovannoni G, et al
    Learning from other autoimmunities to understand targeting of B cells to control multiple sclerosis.
    Brain. 2018 Sep 12. pii: 5095715. doi: 10.1093.
    PubMed     Abstract available


  105. EIJLERS AJC, van Geest Q, Dekker I, Steenwijk MD, et al
    Predicting cognitive decline in multiple sclerosis: a 5-year follow-up study.
    Brain. 2018;141:2605-2618.
    PubMed     Abstract available


    June 2018
  106. MACHADO-SANTOS J, Saji E, Troscher AR, Paunovic M, et al
    The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells.
    Brain. 2018 Jun 4. pii: 5032773. doi: 10.1093.
    PubMed     Abstract available


  107. STANKOFF B, Louapre C
    Can we use regional grey matter atrophy sequence to stage neurodegeneration in multiple sclerosis?
    Brain. 2018;141:1580-1583.
    PubMed    


    May 2018
  108. CAMARA-LEMARROY CR, Metz L, Meddings JB, Sharkey KA, et al
    The intestinal barrier in multiple sclerosis: implications for pathophysiology and therapeutics.
    Brain. 2018 May 30. pii: 5025744. doi: 10.1093.
    PubMed     Abstract available


  109. BARRO C, Benkert P, Disanto G, Tsagkas C, et al
    Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis.
    Brain. 2018 May 30. pii: 5025690. doi: 10.1093.
    PubMed     Abstract available


  110. ESHAGHI A, Marinescu RV, Young AL, Firth NC, et al
    Progression of regional grey matter atrophy in multiple sclerosis.
    Brain. 2018 May 8. pii: 4993898. doi: 10.1093.
    PubMed     Abstract available


  111. LADISLAU L, Suarez-Calvet X, Toquet S, Landon-Cardinal O, et al
    JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis.
    Brain. 2018 May 8. pii: 4993951. doi: 10.1093.
    PubMed     Abstract available


    April 2018
  112. CONRAD BN, Barry RL, Rogers BP, Maki S, et al
    Multiple sclerosis lesions affect intrinsic functional connectivity of the spinal cord.
    Brain. 2018 Apr 10. pii: 4965865. doi: 10.1093.
    PubMed     Abstract available


  113. VAN LANGELAAR J, van der Vuurst de Vries RM, Janssen M, Wierenga-Wolf AF, et al
    T helper 17.1 cells associate with multiple sclerosis disease activity: perspectives for early intervention.
    Brain. 2018 Apr 5. pii: 4961484. doi: 10.1093.
    PubMed     Abstract available


    March 2018
  114. STEYERBERG EW, Claggett B
    Towards personalized therapy for multiple sclerosis: limitations of observational data.
    Brain. 2018 Mar 3. pii: 4919652. doi: 10.1093.
    PubMed    


  115. KALINCIK T
    Reply: Towards personalized therapy for multiple sclerosis: limitations of observational data.
    Brain. 2018 Mar 3. pii: 4919653. doi: 10.1093.
    PubMed    


  116. STEPHENSON EL, Mishra MK, Moussienko D, Laflamme N, et al
    Chondroitin sulfate proteoglycans as novel drivers of leucocyte infiltration in multiple sclerosis.
    Brain. 2018 Mar 1. pii: 4915907. doi: 10.1093.
    PubMed     Abstract available


    February 2018
  117. ARRAMBIDE G, Tintore M, Espejo C, Auger C, et al
    The value of oligoclonal bands in the multiple sclerosis diagnostic criteria.
    Brain. 2018 Feb 16. pii: 4866204. doi: 10.1093.
    PubMed     Abstract available


    January 2018
  118. SMETS I, Fiddes B, Garcia-Perez JE, He D, et al
    Multiple sclerosis risk variants alter expression of co-stimulatory genes in B cells.
    Brain. 2018 Jan 18. pii: 4817414. doi: 10.1093.
    PubMed     Abstract available


    December 2017
  119. KIM RY, Mangu D, Hoffman AS, Kovash R, et al
    Oestrogen receptor beta ligand acts on CD11c+ cells to mediate protection in experimental autoimmune encephalomyelitis.
    Brain. 2017 Dec 8. pii: 4710057. doi: 10.1093.
    PubMed     Abstract available


    October 2017
  120. GRANBERG T, Fan Q, Treaba CA, Ouellette R, et al
    In vivo characterization of cortical and white matter neuroaxonal pathology in early multiple sclerosis.
    Brain. 2017 Oct 10. doi: 10.1093.
    PubMed     Abstract available


    September 2017
  121. ROCCA MA, Sormani MP, Rovaris M, Caputo D, et al
    Long-term disability progression in primary progressive multiple sclerosis: a 15-year study.
    Brain. 2017 Sep 27. doi: 10.1093.
    PubMed     Abstract available


  122. DATTA G, Colasanti A, Rabiner EA, Gunn RN, et al
    Neuroinflammation and its relationship to changes in brain volume and white matter lesions in multiple sclerosis.
    Brain. 2017 Sep 23. doi: 10.1093.
    PubMed     Abstract available


  123. KALINCIK T, Manouchehrinia A, Sobisek L, Jokubaitis V, et al
    Towards personalized therapy for multiple sclerosis: prediction of individual treatment response.
    Brain. 2017;140:2426-2443.
    PubMed     Abstract available


    July 2017
  124. SCOLDING NJ, Pasquini M, Reingold SC, Cohen JA, et al
    Cell-based therapeutic strategies for multiple sclerosis.
    Brain. 2017 Jul 21. doi: 10.1093.
    PubMed     Abstract available


    May 2017
  125. DELMONT E, Manso C, Querol L, Cortese A, et al
    Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy.
    Brain. 2017 May 28. doi: 10.1093.
    PubMed     Abstract available


  126. ZRZAVY T, Hametner S, Wimmer I, Butovsky O, et al
    Loss of 'homeostatic' microglia and patterns of their activation in active multiple sclerosis.
    Brain. 2017 May 24. doi: 10.1093.
    PubMed     Abstract available


  127. HACOHEN Y, Ciccarelli O, Hemingway C
    Abnormal white matter development in children with multiple sclerosis and monophasic acquired demyelination.
    Brain. 2017;140:1172-1174.
    PubMed    


    April 2017
  128. EL BEHI M, Sanson C, Bachelin C, Guillot-Noel L, et al
    Adaptive human immunity drives remyelination in a mouse model of demyelination.
    Brain. 2017;140:967-980.
    PubMed     Abstract available


    March 2017
  129. LONGONI G, Brown RA, MomayyezSiahkal P, Elliott C, et al
    White matter changes in paediatric multiple sclerosis and monophasic demyelinating disorders.
    Brain. 2017 Mar 14. doi: 10.1093.
    PubMed     Abstract available


  130. JURYNCZYK M, Geraldes R, Probert F, Woodhall MR, et al
    Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis.
    Brain. 2017;140:617-627.
    PubMed     Abstract available


    February 2017
  131. PONATH G, Ramanan S, Mubarak M, Housley W, et al
    Myelin phagocytosis by astrocytes after myelin damage promotes lesion pathology.
    Brain. 2017;140.
    PubMed     Abstract available


    June 2016
  132. ARAUJO AQ, Silva MT, Araujo AP
    Zika virus-associated neurological disorders: a review.
    Brain. 2016.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: